Type 2 Diabetes Risk in Young Adults: How GLP-1 Medications Can Help Prevent Progression

New research underscores the need for earlier, more personalized interventions to prevent type 2 diabetes in young adults with prediabetes. Findings show that risk varies significantly among adults aged 18 to 40, particularly for those with high fasting glucose levels or who meet criteria for GLP-1 receptor agonist (GLP-1RA) treatment.

These individuals face a substantially higher risk of progressing to type 2 diabetes within five years. The findings challenge the current one-size-fits-all approach to diabetes prevention and highlight the potential benefits of tailored strategies.

Key Findings from the Study

The research, presented at the American Heart Association’s EPI|Lifestyle Scientific Sessions 2026 (March 17–20), analyzed data from 662 young adults with prediabetes over an average of seven years. The participants were drawn from three major U.S.-based cohorts:

• Hispanic Community Health Study/Study of Latinos
• Coronary Artery Risk Development in Young Adults study
• Framingham Heart Study Third Generation

The study defined prediabetes based on fasting glucose levels of 100 to 125 mg/dL. While hemoglobin A1c data (which measures average blood glucose over two to three months) were not available, researchers collected extensive health data, including BMI, lipid profiles, and blood pressure readings from 1985 to 2011.

GLP-1 Medications and Risk Stratification

Researchers applied existing FDA criteria for GLP-1 drug prescriptions for weight loss to estimate five-year diabetes progression risk. These criteria include:

• A BMI of 30 kg/m² or higher (obesity)
• A BMI of 27 kg/m² or higher (overweight) with at least one weight-related condition, such as high cholesterol or hypertension

Using these benchmarks, the team identified subgroups within the prediabetic population who may benefit most from targeted interventions, including GLP-1 medications.

Why Early Intervention Matters

Diagnosing prediabetes and managing high blood sugar early can prevent or delay the onset of type 2 diabetes and its serious complications, such as:

• Heart disease
• Kidney disease
• Stroke

Despite more than 115 million Americans having prediabetes, an estimated 80% are unaware of their condition. Symptoms may be absent, making regular screening essential for at-risk individuals.

Lifestyle Changes and GLP-1s: A Dual Approach

Experts recommend a combination of lifestyle modifications and, where appropriate, GLP-1 medications to reduce diabetes risk. Key steps include:

• Diet: Adopting a balanced, nutrient-rich diet to manage blood sugar levels.
• Exercise: Engaging in regular physical activity to improve insulin sensitivity.
• Sleep: Prioritizing quality sleep to regulate metabolic health.
• Stress Reduction: Managing stress through mindfulness or other techniques to lower cortisol levels.

For those who qualify, GLP-1 medications—such as semaglutide or liraglutide—can further enhance weight loss and blood sugar control, reducing progression to type 2 diabetes.

What’s Next?

The study has not yet been published in a peer-reviewed journal but offers critical insights into diabetes prevention strategies. Future research may explore the long-term efficacy of GLP-1 medications in young adults with prediabetes and refine risk stratification models.